MDS is a bone marrow failure disorder
MDS is a blood cancer
Learn More >
Season 2: Episode 1:

MDS in ASH 2021 – Are We Already in the Molecular Era?

Dr. Moshe Mittelman and Dr. Drorit Merkel
  • Listen on Spotify

Drs. Moshe Mittelman, of The Tel Aviv Sourasky Medical Center, and Drorit Merkel, of the Sheba Medical Center, both from Tel Aviv University, Israel, discuss several important presentations from the recent 2021 ASH meeting.

They focus on the new IPSS-M classification, discuss the approach to the MDS patient who is currently defined by IPSS/R as belonging to the /lower-risk group but in fact the disease behaves like a higher-risk. Finally, they discuss issues regarding the treatment of patients with HR-MDS: What can be added to hypomethylating agents? Targeted therapy with IDH1/2 inhibition and more…



If you have questions or feedback on this podcast, please feel free to contact us. We would love to hear from you!

Contact Us

Enjoying Our Podcasts?

If you are enjoying our podcasts and other resources, please consider becoming a Professional Member of the MDS Foundation.

Learn More About Membership
Review answers to commonly asked questions or get answers to your questions from an MDS expert